Cabotegravir And Rilpivirine: Efficacy and Safety Study


The KEMRI/MRD-A site operates under a collaborative agreement between the US Army Medical Research Directorate-Africa (MRD-A) and the Kenya Medical Research Institute (KEMRI).  The site is located 260 km northwest of Nairobi in the town of Kericho, in the Southern Rift Valley (SRV) Province of Kenya. The KEMRI/MRD-A Kericho Program was established in 1998 and is located at the Ministry of Health (MoH) Kericho County Hospital. KEMRI is a Government of Kenya para-state corporation established as the national body responsible for carrying out health research in Kenya.

The Kericho Clinical Research Site is part of the NIH networks that include ACTG, IMPAACT and HVTN and operates under the US Military HIV Research Program (MHRP). Since 2003, it has conducted several studies including clinical trials and health economics studies focused on HIV/AIDS, TB, cryptococcal meningitis, Kaposi’s sarcoma, malaria, Ebola, Yellow Fever, MERS-Cov and COVID-19.  

Through support from the PEPFAR program, the Kericho site has been providing comprehensive HIV care, treatment and prevention services through over 400 health facilities covering about 4 million people since 2004. This together with an active and engaged Community Advisory Board (CAB) has endeared the site to the local communities creating a supportive environment for research.

Dr. Josephat Kosgei
Site PI